AMGEN INC. DL-,0001/ US0311621009 /
27/09/2024 08:33:55 | Chg. +0.500 | Volume | Bid08:45:11 | Ask08:45:11 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
285.950EUR | +0.18% | 58 Turnover: 16,615.900 |
285.100Bid Size: 88 | 286.450Ask Size: 88 | 153.39 bill.EUR | - | - |
GlobeNewswire
29/08
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
27/06
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...